Franklin Genomic Advancements ETF (HELX)

BATS: HELX · Real-Time Price · USD

33.92

+0.34 (1.01%)

At close: May 12, 2026, 4:00 PM EDT

33.73

-0.19 (-0.56%)

After-hours: May 12, 2026, 8:00 PM EDT

1.01% (1D)

Assets	$21.81M
Expense Ratio	0.50%
PE Ratio	29.38
Shares Out	650,000
Dividend (ttm)	$0.14
Dividend Yield	0.42%
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	12.52%

Volume	1,196
Open	33.58
Previous Close	33.58
Day's Range	33.58 - 33.92
52-Week Low	24.94
52-Week High	38.17
Beta	1.01
Holdings	66
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

Asset Class Equity

Category Health

Region Global

Stock Exchange BATS

Ticker Symbol HELX

ETF Provider Franklin Templeton

Top 10 Holdings

43.30% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	6.88%
Natera, Inc.	NTRA	6.34%
Krystal Biotech, Inc.	KRYS	6.18%
United Therapeutics Corporation	UTHR	4.34%
Ligand Pharmaceuticals Incorporated	LGND	3.84%
BridgeBio Pharma, Inc.	BBIO	3.76%
AstraZeneca PLC	AZN	3.09%
Adaptive Biotechnologies Corporation	ADPT	3.05%
Samsung Biologics Co.,Ltd.	207940	2.99%
Vertex Pharmaceuticals Incorporated	VRTX	2.82%

View More Holdings

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Full Dividend History

Performance

HELX had a total return of 32.70% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.79%.